PDCD1 and neoplasm: CRISPR/Cas9-mediated PD-1 depletion was proven to augment the ability of CAR-T cells in killing tumor cells in vitro and clearing PD-L1+ tumor xenografts in vivo (Rupp et al., 2017; Choi et al., 2019).